A synthetic opioid up to 100 times more potent than fentanyl is retreating from the U.S. drug supply, at least for now. A new situation summary from the Centers for Disease Control and Prevention, published November 9, 2026, shows carfentanil detections in overdose deaths and drug seizures falling after a peak in the second half …
Carfentanil Overdoses Decline After Mid-2025 Peak, CDC Says

A synthetic opioid up to 100 times more potent than fentanyl is retreating from the U.S. drug supply, at least for now. A new situation summary from the Centers for Disease Control and Prevention, published November 9, 2026, shows carfentanil detections in overdose deaths and drug seizures falling after a peak in the second half of 2025.
Carfentanil is a fentanyl analog, and it remains rare in the illegal drug supply, where it is primarily found mixed with illicitly made fentanyl. Even trace exposure carries outsized danger because of the drug’s strength.
A Drug That Nearly Vanished, Then Returned
Carfentanil caused severe localized overdose outbreaks in the past, then almost disappeared from the American drug supply during 2021 and 2022.
Detection among overdose deaths began climbing again in 2023, rising from 0.02 percent of deaths in the first quarter of that year to 3.20 percent during July through September 2025. The CDC’s updated tracking shows that percentage declining into 2026.
Urine drug testing told the same story. Among specimens that tested positive for fentanyl, the share also positive for carfentanil peaked at 1.73 percent during July through September 2025 before falling.
Testing of illegal drug products and paraphernalia peaked later, during July through December 2025, then decreased during the first half of 2026.
Midwest and Northeast See the Sharpest Spikes
The resurgence was not evenly distributed. The CDC found sharper increases in carfentanil detection among fentanyl-positive urine specimens in the Midwest beginning in 2025.
During the second half of that year, four jurisdictions reported carfentanil in 5 percent or more of illegal opioid samples, and all four were in the Midwest and Northeast.
By January through June 2026, the number of sentinel jurisdictions detecting carfentanil in opioid-positive drug samples had dropped from 13 to 9 out of 15 sites reporting.
Detection across all census regions decreased from the mid-2025 peak into early 2026, though the Midwest, Northeast, and West each saw slight upticks between the first and second quarters of 2026.
Why One Dose of Naloxone May Not Be Enough
The CDC’s guidance for bystanders reflects the drug’s potency. Because carfentanil is so strong, multiple doses of naloxone or additional medical care might be required to reverse an overdose.
Overdose symptoms match those of other opioids: slowed or stopped breathing, drowsiness, disorientation, sedation, pinpoint pupils, and clammy skin. Because of its potency, even small amounts can increase the risk of overdose.
How the CDC Tracks an Emerging Threat
The situation summary draws on three data streams. Urine drug tests conducted by Millennium Health track exposure among patients in behavioral health, primary care, and substance use treatment settings.
The State Unintentional Drug Overdose Reporting System captures postmortem toxicology from 40 funded jurisdictions. Laboratory testing by 18 local public health departments, with 15 reporting complete data, provides early warning of changes in the drug supply itself.
The CDC says it will update the summary every six months, a sign that officials expect carfentanil to remain a moving target. If you or someone in your life uses opioids, carry naloxone, learn the signs of an overdose, and understand that a rescue may take more than one dose.
You can search Narcotics.com’s directory to find NA meetings near you. Call 800-934-1582(Sponsored) to get in contact with a treatment advisor today.
the Take-Away